Clinical Trials Browser

Phase 2 × Non-alcoholic Fatty Liver Disease × 90 days × Clear all

NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease